Download - Access Pharmaceuticals Inc：-访问制药公司.pptVIP

* * * * * * * * * * * * * * * * * * * * * * Company Presentation March 7, 2012 Cowen and Company 32nd Annual Health Care Conference This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard?, the sales of, market opportunities for and planned studies of ProLindac?, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Accesss Annual Report on Form 10 for the year ended December 31, 2010, and other reports filed by the companies with the Securities and Exchange Commission. These materials are not an offer to sell securities and are not soliciting an offer to buy securities.?  * Safe Harbor Statement * About Access Pharmaceuticals Access Pharmaceuticals is an emerging biopharmaceutical company focused on the treatment of cancer and cancer supportive care. The Company currently has one marketed product and two products in Phase II clinical trials. Approved product addressing a large unmet medical need MuGard is a patient friendly treatment for oral mucositis addressing a $1.0 billion plus market Two Phase 2 oncology assets Proprietary compounds, ProLindac and Thiarabine, are in Phase 2 clinical trials and target multi-billion dollar cancer markets, including metastatic colorectal and ovarian Attractive proprietary drug delivery platforms CobOral and CobaCyte, two drug delivery platforms based upon Vitamin B-12 absorption, create multiple product opportunities and provide diversification of risk Active partnering strategies Multiple pre-licensing partnerships / collaborations with pharma companies validate drug delivery techn